Journal article
No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy
Journal of acquired immune deficiency syndromes (1999), v 59(3)
01 Mar 2012
PMID: 22083073
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: Controversy continues regarding the extent of ongoing viral replication in HIV-1-infected patients on effective antiretroviral therapy (ART). Adding an additional potent agent, such as raltegravir, to effective ART in patients with low-level residual viremia may reveal whether there is ongoing HIV-1 replication.
Methods: We previously reported the outcome of a randomized placebo-controlled study of raltegravir intensification in patients on ART with HIV-1 RNA,50 copies per milliliter that showed no effect on residual viremia measured by single copy assay. We now report the effects of raltegravir intensification in that trial on other potential measures of ongoing HIV-1 replication as follows: 2-LTR HIV-1 circles, total cellular HIV-1 DNA, and T-cell activation.
Results: Of 50 patients tested, 12 (24%) had 2-LTR circles detected at baseline. Patients who were 2-LTR-positive had higher plasma HIV-1 RNA and HIV-1 DNA levels than 2-LTR-negative individuals. At week 12 of raltegravir intensification, there was no change from baseline in 2-LTR circles, in total HIV-1 DNA or in the ratio of 2-LTR circles to total HIV-1 DNA. There was also no change in markers of T-cell activation.
Conclusions: In HIV-1-infected individuals on effective ART, we find no evidence of ongoing viral replication in the blood that is suppressible by raltegravir intensification. The results imply that raltegravir intensification alone will not eradicate HIV-1 infection.
Metrics
Details
- Title
- No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy
- Creators
- Rajesh T. Gandhi - Harvard UniversityRobert W. Coombs - University of WashingtonEllen S. Chan - Harvard UniversityRonald J. Bosch - Harvard UniversityLu Zheng - Harvard UniversityDavid M. Margolis - University of North CarolinaSarah Read - National Institutes of HealthBeatrice Kallungal - Social and Scientific Systems (United States)Ming Chang - Department of VirologyErin A. Goecker - Department of VirologyAnn Wiegand - National Institutes of HealthMary Kearney - National Institutes of HealthJeffrey M. Jacobson - Drexel UniversityRichard D'Aquila - Vanderbilt UniversityMichael M. Lederman - Case Western Reserve UniversityJohn W. Mellors - University of PittsburghJoseph J. Eron - Harvard UniversityAIDS Clinical Trials Grp ACTG A524
- Publication Details
- Journal of acquired immune deficiency syndromes (1999), v 59(3)
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 7
- Grant note
- Bristol-Myers Squibb AI069450 / Colorado ACTU CTU AI50410 / CFAR 204VC009; 1U01AI068636 / Virology Support Laboratory of the AIDS Clinical Trials Group Central Group 5UO1 AI069502-03 / San Francisco General Hospital CTU Roche Molecular Systems 2P30 AI060354-06 / Harvard University Center for AIDS Research (National Institute of Health) GlaxoSmithKline/Viiv U01 AI069452 / Alabama Therapeutics CRS CTU Merck Sharp and Dohme, Corp. U01AI068636; AI 068634 / National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) P30-AI-27757 / University of Washington Center for AIDS Research AI-38858 / AIDS Clinical Trials Group Virology Specialty Laboratory AI69511-02 / University of Rochester CTU AI069532; AI-27665 / NYC HHC at Bellevue Hospital Center AI69423-03 / BSN-University of North Carolina AIDS Clinical Trials Unit CTU 25XS119 / National Cancer Institute/Science Applications International Corporation G08LM008830 / NATIONAL LIBRARY OF MEDICINE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM) R01 AI066992-04A1; G08LM008830-01; U01 AI 694722 / National Institute of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Virco U01AI069501 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) AI 069494-01 / RN-University of Pittsburgh CTU Tibotec 1U01AI069472 / Yandow, RN, BSN-Harvard Massachusetts General Hospital CTU Merck; Merck & Company RR025747 / CTSA; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) AI069419 / Cornell CTU HIV Prevention and Treatment CRS AI069434 / University of Washington, Seattle CTU UL1RR025747 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) AI069495 / BSN-Washington University in St. Louis CTU AI069470 / Harlem Family Health Center CTU 5U01 AI069484 / Duke University Medical Center CTU M01 RR-00032; RR025780; 5-MO1 RR00044 / GCRC; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) U01 AI069472-04 / Beth Israel Deaconess (Partners/Harvard) CTU Gilead; Gilead Sciences AI 069501 / MetroHealth CTU AI069424 / Harbor UCLA Medical Center CTU AI069471 / RN-Northwestern University CTU AI069556 / PA-C-Stanford University CTU
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000300767400007
- Scopus ID
- 2-s2.0-84859752894
- Other Identifier
- 991019335326304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases